Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lantern Pharma Inc. - Common Stock (NQ: LTRN )

3.772 +0.032 (+0.86%)
Streaming Delayed Price Updated: 2:26 PM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lantern Pharma Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Oncotarget Publishes New Data by Lantern Pharma, an AI Company Developing Cancer Therapies, Further Supporting Clinical Advancement of LP-284, a Novel Synthetically Lethal Drug Candidate for Non-Hodgkin’s Lymphomas
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma Receives FDA Clearance of IND Application for Drug Candidate LP-184 in Solid Tumors
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma's Earnings: A Preview
Via Benzinga
Lantern Pharma Leverages AI Platform, RADR®, to Develop Breakthrough Antibody Drug Conjugates (ADCs) in Collaboration with Bielefeld University
From Lantern Pharma
Via Business Wire
3 Penny Stocks to Buy as the AI Sector Transforms Every Industry in 2023
These AI penny stocks could potentially offer potent long-term value at tremendously attractive prices at this time 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2023
Via Benzinga
Lantern Pharma to Present at the Lytham Partners Spring 2023 Investor Conference Thursday, May 18th at 9:00 a.m. ET
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma Reports First Quarter 2023 Financial Results and Operational Highlights
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma to Report First Quarter 2023 Operating & Financial Results on May 9, 2023 at 4:30 p.m. ET
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma Develops Top-Ranked AI Algorithms to Predict the Blood-Brain-Barrier Permeability of Any Compound
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma Receives Notice of Allowance for Composition of Matter Patent Covering Drug Candidate LP-284
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma Announces First Patient Dosed in the Phase 2 Study, Harmonic™, for LP-300 in Never Smokers with Advanced Non-Small Cell Lung Cancer
From Lantern Pharma Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Lantern Pharma to Present at Upcoming Scientific Conferences and Webinars
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Operational Highlights
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma to Present at the American Association for Cancer Research (AACR) Annual Meeting
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2022 Operating & Financial Results on March 20, 2023 at 4:30 p.m. ET
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma Confirms It Had No Exposure to Silicon Valley Bank (SVB), Silvergate Bank, or Signature Bank
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma Announces New Data and Development Focus for LP-100 with PARP Inhibitors
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma to Host Virtual KOL Webinar on Synthetic Lethality, the Powerful Mechanism of Action Behind Several of Lantern’s Drug Candidates, Featuring Zoltan Szallasi, M.D.
From Lantern Pharma
Via Business Wire
Lantern Pharma Announces Formation of Starlight Therapeutics to Advance Transformative Therapies for CNS (Central Nervous System) and Brain Cancers
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma Expands Clinical Leadership Team to Further Advance its Ongoing and Upcoming Clinical Trials
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma and TTC Oncology Establish AI Collaboration to Expand the Clinical Development of Drug Candidate TTC-352
From Lantern Pharma Inc.
Via Business Wire
7 AI Penny Stocks That Could Skyrocket in 2023
AI penny stocks represent great potential and high returns, given the fact this technology is only beginning to pervade society. 
Via InvestorPlace
Lantern Pharma Further Enhances Capabilities of its AI Drug Discovery Platform, RADR®, with Product Development Roadmap for the Development of Antibody Drug Conjugates
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma Receives Pre-IND Feedback from the FDA, Clearing a Path for Drug Candidate LP-184’s Phase 1 Clinical Trial in Q2 2023
From Lantern Pharma Inc.
Via Business Wire
FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in Mantle Cell Lymphoma
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma Announces Positive New Data for its Drug Candidate LP-284 for Mantle Cell Lymphoma (MCL) at the American Society of Hematology (ASH) 2022 Annual Meeting
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma Announces Development of Drug Candidate LP-184 for Triple Negative Breast Cancer (TNBC) at the San Antonio Breast Cancer Symposium (SABCS)
From Lantern Pharma Inc.
Via Business Wire
BioMedNewsBreaks – Lantern Pharma Inc. (NASDAQ: LTRN) to Present at RHK Capital Disruptive Growth Conference
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.